RecruitingNCT06044584

Unveiling Physiological and Psychosocial Pain Components with an Artificial Intelligence Based Telemonitoring Tool

Unveiling Physiological and Psychosocial Pain Components with an Artificial Intelligence Based Telemonitoring Tool (pAIn-sense)


Sponsor

ETH Zurich

Enrollment

150 participants

Start Date

Sep 29, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The pAIn-sense study aims to revolutionize the monitoring and treatment of chronic pain, a major health concern that significantly impacts psychological well-being and quality of life. Traditional approaches to pain management face challenges like unspecific drug use and high healthcare costs, and they often leave patients dissatisfied. PAIn-sense aims at comprehensively understanding pain from both physical and emotional perspectives. To accomplish this, the study will employ advanced Artificial Intelligence (AI) techniques and wearable sensing technology. The study aims to monitor patients continuously, during both day and night activities, to gather a multidimensional set of data on their physiological, psychosocial, and pain conditions.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

  • Ongoing nociceptive pain after an injury or Neuropathic pain (acute or chronic)
  • Familiar with using electronic devices

Exclusion Criteria2

  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
  • Unable or not willing to give informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

Observational study with no intervention - Monitoring


Locations(4)

Unita Spinale ASL

Pietra Ligure, Savona, Italy

Neuroengineering Lab

Zurich, Canton of Zurich, Switzerland

Balgrist University Hospital

Zurich, Canton of Zurich, Switzerland

CRR Suva (Clinique romande de réadaptation)

Sion, Valais, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06044584


Related Trials